ArticleThe Journal of experimental medicine2014
Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
Article in The Journal of experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 80 citations in OpenAlex.
- Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data.Journal of the International AIDS Society · 2025Trial
- Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.Nature medicine · 2018Trial
- Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.The Journal of clinical investigation · 2015Trial
- Retinoids enhance NK effector function against HIV-infected CD4 T cells.Journal of virology · 2026Article
- The Humanized Mouse Model: What Added Value Does It Offer for HIV Research?Pathogens (Basel, Switzerland) · 2023Review
- HIV-1 Vpu restricts Fc-mediated effector functions in vivo.Cell reports · 2022Article
- Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.The Journal of experimental medicine · 2022Article
- Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies.Frontiers in immunology · 2022Article
- Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.Nature communications · 2021Article
- Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease.The Journal of experimental medicine · 2021Article
- Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.bioRxiv : the preprint server for biology · 2021Article
- Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis.Nature communications · 2021Article
- Article
- Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.bioRxiv : the preprint server for biology · 2020Article
- Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Harnessing Avidity: Quantifying the Entropic and Energetic Effects of Linker Length and Rigidity for Multivalent Binding of Antibodies to HIV-1.Cell systems · 2019Article
- eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody.Journal of virology · 2019Article
- Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.Immunity · 2019Article
- Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.Nature medicine · 2019Review
- Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.Immunity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 3 countries.
Funding
Abstract
Antibody-mediated immunotherapy is effective in humanized mice when combinations of broadly neutralizing antibodies (bNAbs) are used that target nonoverlapping sites on the human immunodeficiency virus type 1 (HIV-1) envelope. In contrast, single bNAbs can control simian-human immunodeficiency virus (SHIV) infection in immune-competent macaques, suggesting that the host immune response might also contribute to the control of viremia. Here, we investigate how the autologous antibody response in intact hosts can contribute to the success of immunotherapy. We find that frequently arising antibodies that normally fail to control HIV-1 infection can synergize with passively administered bNAbs by preventing the emergence of bNAb viral escape variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.